aTYR PHARMA INC 8-K

What Happened

• aTyr Pharma, Inc. (NASDAQ: ATYR) announced that Nasdaq notified the company on Dec 4, 2025 that its common stock had closed below the $1.00 minimum bid-price requirement for 30 consecutive business days. The company initially had until June 2, 2026 to regain compliance.
• On June 3, 2026 Nasdaq granted a second 180-day compliance period, extending the deadline to Nov 30, 2026. To regain compliance the stock must close at $1.00 or more for at least 10 consecutive business days (the Staff may extend this to up to 20 business days). The company said it may consider a reverse stock split if necessary.

Key Details

• Notice of deficiency received: Dec 4, 2025.
• Initial compliance deadline: June 2, 2026; second compliance deadline: Nov 30, 2026 (additional 180 days).
• Minimum requirement to cure: $1.00+ closing bid for at least 10 consecutive business days (possible extension up to 20 days).
• Possible cure actions: monitor stock price and evaluate options including a reverse stock split; if noncompliant, Nasdaq may begin delisting procedures (company can appeal).

Why It Matters

• A continued failure to meet Nasdaq’s $1.00 bid-price rule can lead to delisting, which would reduce liquidity and could limit investor access and valuation. The extension to Nov 30, 2026 gives aTyr time to cure the deficiency, but there is no guarantee an appeal would succeed if delisting is initiated. Investors should monitor the company’s stock price, any announced corporate actions (e.g., a reverse split), and further Nasdaq communications.